Velactis (cabergoline) is a POM marketed by Ceva Animal Health, used in the herd management programme of dairy cows as an aid in abrupt drying-off, by reducing milk production.
The product was authorised through the European Medicines Agency (EMA) in December 2015 and was first sold in the UK in April 2016.
The VMD says it has been made aware of reports of serious adverse events, predominantly occurring in Denmark, involving recumbency (lying down and unable to rise) and some deaths. Most adverse events occurred within 8 to 24 hours following product administration. Anecdotal evidence suggests that hypocalcaemia treatments may be successful in reversing clinical signs.
Ceva has decided to stop further distribution of the product in Europe voluntarily, pending the outcome of further investigations to assess a possible causal link between the product and the adverse events reported.
The VMD, EMA, other agencies throughout Europe and the MAH are working closely to monitor the situation.
The VMD highlights that due to the nature and use of the product there is no risk to human health or consumer safety.
Vets and dairy farmers are strongly encouraged to report any adverse events associated with use of Velactis to the VMD using its online reporting form or directly to Ceva for further investigation by the MAH as necessary.
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.